ROCHE HLDGS AG (RHHBY)

32.45
0.24 0.76
OTC
Prev Close 32.20
Open 32.57
Day Low/High 32.37 / 32.61
52 Wk Low/High 26.30 / 32.72
Volume 1.21M
Exchange OTC
Shares Outstanding 702.56B
Market Cap 183.28B
Div & Yield N.A. (N.A)
Roche Launches UPath Enterprise Software With Improved Speed, Performance And Usability For Digital Pathology

Roche Launches UPath Enterprise Software With Improved Speed, Performance And Usability For Digital Pathology

- Innovative design integrates powerful imaging and analysis tools for more efficient workflow

Roche To Develop Companion Diagnostic Test To Help Identify Patients Eligible For Anti-PD-1 Therapy Based On Biomarker Expression, Not Location, Of Solid Tumors

Roche To Develop Companion Diagnostic Test To Help Identify Patients Eligible For Anti-PD-1 Therapy Based On Biomarker Expression, Not Location, Of Solid Tumors

- Roche collaborates with Merck to develop companion diagnostic for use with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in advanced solid tumors with mismatch repair deficiency (dMMR)

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks finished the day higher on Monday as gains by tech stocks offset concerns over the fate of U.S.-China trade talks, and after the U.K. delayed a parliamentary vote on Brexit.

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

U.S. stock futures turn mixed as investors continue to express concerns over the fate of U.S.-China trade talks; Tesla's Elon Musk says, 'I do not respect the SEC'; Carlos Ghosn and Nissan are indicted in Japan for underreporting the former chairman's pay.

FDA Approves Genentech's Tecentriq In Combination With Avastin And Chemotherapy For The Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

FDA Approves Genentech's Tecentriq In Combination With Avastin And Chemotherapy For The Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Kadcyla Cut The Risk Of Disease Recurring By Half Compared To Herceptin In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech's Kadcyla Cut The Risk Of Disease Recurring By Half Compared To Herceptin In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease...

FDA Grants Priority Review To Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Extensive-Stage Small Cell Lung Cancer

FDA Grants Priority Review To Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control In The Largest Pivotal Study To Date Of Children With Hemophilia A With Factor VIII Inhibitors

Genentech's Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control In The Largest Pivotal Study To Date Of Children With Hemophilia A With Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the primary analysis of the Phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab-kxwh) prophylaxis in children younger than 12 years of age with hemophilia...

New Venclexta® Data Demonstrate Deep Responses In Two Of The Most Common Types Of Leukemia

New Venclexta® Data Demonstrate Deep Responses In Two Of The Most Common Types Of Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the Venclexta ® (venetoclax) clinical development program, including longer-term results from the Phase III MURANO study in people with previously treated...

Roche Launches First IVD Pan-TRK Immunohistochemistry Assay

Roche Launches First IVD Pan-TRK Immunohistochemistry Assay

- The VENTANA pan-TRK (EPR17341) Assay[1] is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types

Genentech Announces FDA Grants Venclexta Accelerated Approval For People With Newly-Diagnosed Acute Myeloid Leukemia Or Those Who Are Ineligible For Intensive Induction Chemotherapy

Genentech Announces FDA Grants Venclexta Accelerated Approval For People With Newly-Diagnosed Acute Myeloid Leukemia Or Those Who Are Ineligible For Intensive Induction Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Genentech To Present New Data From Its Industry-Leading Hematology Portfolio At The American Society Of Hematology (ASH) 2018 Annual Meeting

Genentech To Present New Data From Its Industry-Leading Hematology Portfolio At The American Society Of Hematology (ASH) 2018 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60...

Roche Diagnostics To Replace CoaguChek® XS PT Test Strips

Roche Diagnostics To Replace CoaguChek® XS PT Test Strips

INDIANAPOLIS, Oct. 31, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY): This notification supplements previous Urgent Medical Device Correction (UMDC) communications initially issued by Roche Diagnostics on September 12, 2018 and updated on...

Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities

Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta ® (venetoclax) in combination with Gazyva ® (obinutuzumab) in people with previously...

New Stairway Study Data Shows Potential For Extended Durability With Faricimab In Wet Age-Related Macular Degeneration (AMD)

New Stairway Study Data Shows Potential For Extended Durability With Faricimab In Wet Age-Related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration...

Genentech Announces FDA Approval Of XOFLUZA (Baloxavir Marboxil) For Influenza

Genentech Announces FDA Approval Of XOFLUZA (Baloxavir Marboxil) For Influenza

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors In People With NTRK Fusion-Positive Solid Tumors

Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors In People With NTRK Fusion-Positive Solid Tumors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized...

Genentech's Tecentriq In Combination With Abraxane Improves Outcomes As An Initial Treatment For People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Genentech's Tecentriq In Combination With Abraxane Improves Outcomes As An Initial Treatment For People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane ® [albumin-bound paclitaxel; nab-paclitaxel]) for the...

FDA Approves Label Update For Genentech's Rituxan (Rituximab) In Two Rare Forms Of Vasculitis

FDA Approves Label Update For Genentech's Rituxan (Rituximab) In Two Rare Forms Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

- Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease...

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from...

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of studies across its industry-leading oncology portfolio of approved and investigational medicines will be presented at the European...

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.